Kiniksa Pharmaceuticals (KNSA)
(Real Time Quote from BATS)
$25.62 USD
+0.46 (1.83%)
Updated Sep 17, 2024 11:32 AM ET
2-Buy of 5 2
D Value D Growth F Momentum F VGM
Brokerage Reports
Kiniksa Pharmaceuticals, Ltd. [KNSA]
Reports for Purchase
Showing records 61 - 80 ( 112 total )
Company: Kiniksa Pharmaceuticals, Ltd.
Industry: Medical - Biomedical and Genetics
Early Expansion Efforts for Mavri and Vixa Look Promising
Provider: WEDBUSH SECURITIES INC.
Analyst: NIERENGARTEN D
Company: Kiniksa Pharmaceuticals, Ltd.
Industry: Medical - Biomedical and Genetics
Company: Kiniksa Pharmaceuticals, Ltd.
Industry: Medical - Biomedical and Genetics
Carry On, Carry On RHAPSODY Readout and Other Updates in 2H20
Provider: WEDBUSH SECURITIES INC.
Analyst: NIERENGARTEN D
Company: Kiniksa Pharmaceuticals, Ltd.
Industry: Medical - Biomedical and Genetics
COVID-19 Impact on Coverage Universe: Week of April 20 Update
Provider: WEDBUSH SECURITIES INC.
Analyst: NIERENGARTEN D
Company: Kiniksa Pharmaceuticals, Ltd.
Industry: Medical - Biomedical and Genetics
Company: Kiniksa Pharmaceuticals, Ltd.
Industry: Medical - Biomedical and Genetics
Company: Kiniksa Pharmaceuticals, Ltd.
Industry: Medical - Biomedical and Genetics
Scratch Here to Reveal Ph 2a Prurigo Nodularis Data in April
Provider: WEDBUSH SECURITIES INC.
Analyst: NIERENGARTEN D
Company: Kiniksa Pharmaceuticals, Ltd.
Industry: Medical - Biomedical and Genetics
COVID-19 Impact on Coverage Universe: Week of March 30 Update
Provider: WEDBUSH SECURITIES INC.
Analyst: NIERENGARTEN D
Company: Kiniksa Pharmaceuticals, Ltd.
Industry: Medical - Biomedical and Genetics
COVID-19 Impact on Coverage Universe: Week of March 30 Update
Provider: WEDBUSH SECURITIES INC.
Analyst: NIERENGARTEN D
Company: Kiniksa Pharmaceuticals, Ltd.
Industry: Medical - Biomedical and Genetics
Mavrilimumab Helps COVID-19 Patients; Supports Anti- Inflammatory Profile
Provider: WEDBUSH SECURITIES INC.
Analyst: NIERENGARTEN D
Company: Kiniksa Pharmaceuticals, Ltd.
Industry: Medical - Biomedical and Genetics
HEALTHCARE - The Week Ahead in Life Sciences
Provider: WEDBUSH SECURITIES INC.
Analyst: NIERENGARTEN D
Company: Kiniksa Pharmaceuticals, Ltd.
Industry: Medical - Biomedical and Genetics
Company: Kiniksa Pharmaceuticals, Ltd.
Industry: Medical - Biomedical and Genetics
Company: Kiniksa Pharmaceuticals, Ltd.
Industry: Medical - Biomedical and Genetics
Company: Kiniksa Pharmaceuticals, Ltd.
Industry: Medical - Biomedical and Genetics
Company: Kiniksa Pharmaceuticals, Ltd.
Industry: Medical - Biomedical and Genetics
Kite Collaboration for Mavrilimumab CAR-T Study Makes Perfect Sense
Provider: WEDBUSH SECURITIES INC.
Analyst: NIERENGARTEN D
Company: Kiniksa Pharmaceuticals, Ltd.
Industry: Medical - Biomedical and Genetics
Final Ph 2 Rilonacept Data Portends Successful RHAPSODY Readout 2H20
Provider: WEDBUSH SECURITIES INC.
Analyst: NIERENGARTEN D
Company: Kiniksa Pharmaceuticals, Ltd.
Industry: Medical - Biomedical and Genetics
HEALTHCARE - The Week Ahead in Life Sciences
Provider: WEDBUSH SECURITIES INC.
Analyst: NIERENGARTEN D
Company: Kiniksa Pharmaceuticals, Ltd.
Industry: Medical - Biomedical and Genetics
Company: Kiniksa Pharmaceuticals, Ltd.
Industry: Medical - Biomedical and Genetics
3Q19 Financials; Looking Ahead to Data-Rich 2020, Ph 2 Rilonacept Data at AHA
Provider: WEDBUSH SECURITIES INC.
Analyst: NIERENGARTEN D